Showing 1 - 6 results of 6 for search 'Nathan R Foster', query time: 0.03s Refine Results
  1. 1
    Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas.

    Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. by Harry H Yoon, Jared M Orrock, Nathan R Foster, Daniel J Sargent, Thomas C Smyrk, Frank A Sinicrope

    Published 2012-01-01
    Get full text
    Article
  2. 2
    Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cancer Treatment Group Study N044E

    Pemetrexed, Carboplatin, and Concomitant Radiation followed by Surgery for Locally Advanced Esophageal Cancer: Results of a Planned Interim Toxicity Analysis of North Central Cance... by Rajini Katipamula, Aminah Jatoi M.D., Nathan R. Foster, Francis Nichols, Joseph Rubin, Matthew Callister, Leonard Gunderson, Steven Alberts

    Published 2008-01-01
    Get full text
    Article
  3. 3
    Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.

    Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial. by Shernan G Holtan, Preston D Steen, Nathan R Foster, Charles Erlichman, Fabiola Medeiros, Matthew M Ames, Stephanie L Safgren, David L Graham, Robert J Behrens, Matthew P Goetz

    Published 2012-01-01
    Get full text
    Article
  4. 4
    Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma developmentResearch in context

    Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma developmentResearch in context by Tianshun Zhang, Qiushi Wang, Wei-Ya Ma, Keke Wang, Xiaoyu Chang, Michele L. Johnson, Ruihua Bai, Ann M. Bode, Nathan R. Foster, Gary W. Falk, Paul J. Limburg, Prasad G. Iyer, Zigang Dong

    Published 2019-11-01
    Get full text
    Article
  5. 5
    MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.

    MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. by Thomas Pavelitz, Lindsay Renfro, Nathan R Foster, Amber Caracol, Piri Welsch, Victoria Valinluck Lao, William B Grady, Donna Niedzwiecki, Leonard B Saltz, Monica M Bertagnolli, Richard M Goldberg, Peter S Rabinovitch, Mary Emond, Raymond J Monnat, Nancy Maizels

    Published 2014-01-01
    Get full text
    Article
  6. 6
    Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers

    Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers by Gretchen E Glaser, Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, Nathan R Foster, Erik J Asmus, Andrea Wahner Hendrickson, Aminah Jatoi, Matthew S Block, Carrie L Langstraat, Tri A Dinh, Matthew W Robertson, John K Camoriano, Kristina A Butler, John A Copland, S John Weroha

    Published 2020-10-01
    Get full text
    Article

Search Tools: